FDA Taking Comments on BsUFA II Review Assessment Project

For the next generation of the FDA’s biosimilar user fee program, the agency is proposing a new model for reviewing 351(k) applications — allowing for additional communication between review teams and sponsors through development meetings across the submission timeline.
Source: Drug Industry Daily